AnaptysBio Inc (ANAB)
23.77
-0.48
(-1.98%)
USD |
NASDAQ |
Jun 14, 16:00
23.66
-0.11
(-0.46%)
After-Hours: 20:00
AnaptysBio Accounts Receivable (Quarterly): 7.089M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 7.089M |
December 31, 2023 | 6.851M |
September 30, 2023 | 3.269M |
June 30, 2023 | 3.182M |
March 31, 2023 | 1.523M |
December 31, 2022 | 1.419M |
September 30, 2022 | 1.18M |
June 30, 2022 | 1.033M |
March 31, 2022 | 0.921M |
December 31, 2021 | 0.876M |
September 30, 2021 | 0.761M |
June 30, 2021 | 0.642M |
March 31, 2021 | 1.247M |
December 31, 2020 | 0.00 |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | 5.00M |
December 31, 2019 | |
September 30, 2019 |
Date | Value |
---|---|
June 30, 2019 | 5.00M |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 | 5.00M |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.00 |
December 31, 2016 | 1.225M |
September 30, 2016 | 0.86M |
June 30, 2016 | 0.98M |
March 31, 2016 | 1.191M |
December 31, 2015 | 1.226M |
September 30, 2015 | 1.913M |
June 30, 2015 | 2.757M |
December 31, 2014 | 1.455M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2020
7.089M
Maximum
Mar 2024
2.500M
Average
1.333M
Median
Accounts Receivable (Quarterly) Benchmarks
XOMA Corp | 0.003M |
Fate Therapeutics Inc | 0.858M |
Ocular Therapeutix Inc | 26.55M |
Apellis Pharmaceuticals Inc | 267.84M |
Sutro Biopharma Inc | 31.30M |